Interferon alpha for the treatment of superficial bladder cancer

Advances in Experimental Medicine and Biology

Volumn 462, Issue , 1999, Pages 371-386

  Naitoh, J ^a   Franklin, J ^a   O'Donnell, M A ^a   Belldegrun, A S ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON;

BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SUPERFICIAL CANCER; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

EID: 0033281642     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4737-2_29     Document Type: Conference Paper

References (59)

1. Immunotherapy of Bladder Cancer
2. Bacillus Calmette-Guerin Immunotherapy
3. Complications of Bacillus Calmette-Guerin Immunotherapy
4. Immunotherapeutic Alternatives in Superficial Bladder Cancer
5. Effects of Bacillus Calmette-Guerrin and Interferon alpha on Human Bladder Cancer in vitro
6. Antiproliferative Activities of Interferons Against Human Bladder Carcinoma Cell Lines in vitro
7. Cancer statistics, 1996
8. Intravesical Bacillus Calmette-Guerin Therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial
9. Natural History of Superficial Bladder Cancer
10. Principles of Intravesical Chemotherapy and Immunotherapy
11. The Plight of the Patient with Carcinoma in situ of the Bladder
12. Bacillus Calmette-Guerin Therapy Alters the Progression of Superficial Cancer
13. New techniques in management and treatment of superficial bladder cancer
14. BCG in Perspective: Advances in the treatment of superficial bladder cancer
15. Local Toxicity Patterns Associated with Intravesical bacillus Calmette-Guerrin: A Southwest Oncology Group Study
16. Virus inference: I. The interferon
17. Interferon-a,b,g: Basic principles and preclinical studies
18. The Interferons. Mechanism of Action and Clinical Applications
19. Interferon-a,b,g: Basic principles and preclinical studies
20. The Effects of Recombinant Human Interferon-Gamma on a Panel of Uman Bladder Cancer Cell Lines
21. Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation
22. Evaluation of local immune response after intravesical bacille Calmette-Guerin treatemnt for superficial bladder cancer
23. Interferon alpha can alter the Lytic Susceptibility of Murine Bladder Transitional Cell Carcinoma (MBT-2) by Their Original Poor Specific Cytotoxic Tumor Infiltrating Lymphocytes
24. Expression of Adhesion Molecules by Bladder Cancer Cells: Modulation by Interferon-Gamma and Tumor Necrosis Factor
25. Immunomodulatory effect of interferon-a2b on natural killer cells and T lymphocytes from patients with transitional cell carcinoma of the bladder
26. Prophylactic Intracavitary Treatment with Interferon alpha Increases Interferon gamma production by Peripheral Blood Mononuclear Cells in Patients with Superficial Transitional Cell Carcinoma of the Bladder
27. In vitro antiproliferative effect of interferon alpha in solid tumors: A potential predictive test
28. Prophylaxis of superficial bladder cancer with mitomycin or interferon alpha-2b: Results of a multicentric Italian study
29. Systemic IFN-alpha treatment of multiple bladder papilloma grade-I or II patients: Pilot study
30. Application of human leukocyte interferon in patients with urinary bladder papillomatosis, breast cancer, and melanoma
31. Intralesional alpha interferon therapy in papillary superficial transitional cell carcinoma of the bladder: A pilot study
32. Fluorescence Detection of Bladder Carcinoma
33. Application of human leukocyte interferon in patients with urinary bladder papillomatosis, breast cancer, and melanoma
34. Alpha lymphoblastoid interferon for non-invasive bladder cancer
35. Alpha-interferon in superficial bladder cancer: A Northern California Oncology Group Study
36. A randomized controlled study of intravesical a-2b-interferon in carcinoma in situ of the bladder
37. Intravesical treatment of bladder cancer with recombinant human interferon-b
38. Gamma-interferon in the therapeutic and prophylactic management of superficial bladder cancer
39. Gamma-interferon in the therapeutic and prophylactic management of superficial bladder cancer
40. Intravesical instillation of beta-interferon in the treatment of bladder cancer
41. Intravesical interferon alpha-2b administration in the treatment of superficial bladder cancer
42. Interferon alpha 2a in superficial bladder cancer prophylaxis: Toleration and long-term follow-up. A phase I-II study
43. Prophylaxis of superficial bladder cancer with mitomycin or interferon alpha-2b: Results of a multicentric Italian study
44. Prophylaxis of superficial bladder cancer with mitomycin or interferon alpha-2b: Results of a multicentric Italian study
45. How effective is topical alpha-2b interferon in preventing recurrence of superficial bladder cancer?
46. Interferons modify in vitro proliferation of human bladder transitional cell carcinoma in the presence of doxorubicin and mitomycin C
47. BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study
48. A prospective, randomized study of intravesical BCG and interferon in superficial bladder cancer
49. Intravesical Immunoprophylaxis in Recurrent Superficial Bladder Cancer (Stage T1): Multicenter Trial Comparing BCG and Interferon-Alpha
50. Results at 43 Months' Follow-up of a Double Blind, Randomized, Prospective Clinical Trial Using Intravesical Interferon Alpha 2b in the Prophylaxis of Stage pT1 Trasitional Cell Carcinoma of the Bladder
51. Results at 43 Months' Follow-up of a Double Blind, Randomized, Prospective Clinical Trial Using Intravesical Interferon Alpha 2b in the Prophylaxis of Stage pT1 Trasitional Cell Carcinoma of the Bladder (Editorial)
52. Interferon-a2b instillation prophylaxis in superficial bladder cancer - A prospective, controlled three-arm trial
53. Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: Interferon-a2b with epirubicin
54. A comparison of the local immune response to intravesical alpha-interferon and Bacillus Calmette-Guerin (BCG) in patients with superficial bladder cancer
55. Pharmacological Biocompatibility between intravesical preparations of BCG and Interferon-Alfa 2B
56. A Low Dose Bacillus Calmette-Guerrin Regimen in Superficial Bladder Cancer Therapy: Is It Effective?
57. Bacillus Calmette-Guerin plus intravesical interferon alpha-2β in patients with superficial bladder cancer
58. Experimental and Clinical Evidence of Enhancement of BCG Efficacy by Adding Interferon-Alpha